The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

Exclusion Criteria

• •Excessive alcohol consumption (weekly ethanol intake: males \< 210 g, females \< 140 g)
• •Tumor lesions previously treated with targeted therapy, immunotherapy, TACE, or radiotherapy
• •Pregnant or breastfeeding women, or positive pregnancy test at baseline
• •Central nervous system metastases diagnosed by CT, MRI, or PET-CT
• •Participation in another clinical drug or therapy trial within 4 weeks before first study dose
• •Major surgery within 4 weeks prior to first study dose, or incomplete recovery from surgery
• •Radiotherapy within 2 weeks before first study dose
• •History or presence of primary immunodeficiency or active autoimmune disease
• •History of organ transplantation or hematopoietic stem cell transplantation
• •Current use of immunosuppressants or corticosteroids (\>10 mg/day prednisone or equivalent) within 2 weeks
• •Positive for HIV antibody or Treponema pallidum antibody, or active hepatitis B/C infection
• •Allergy to recombinant humanized PD-1 monoclonal antibody, VEGF monoclonal antibody, or components
• •Symptomatic pleural effusion, pericardial effusion, or ascites requiring clinical intervention
• •Severe cardiovascular disease within 12 months (e.g., CAD, CHF ≥ II, arrhythmias, MI)
• •Events within 6 months before first dose (e.g., DVT, PE, MI, PCI, ACS, CABG, stroke, TIA, embolism)
• •History of GI surgery, obstruction, bleeding, dysfunction, or malabsorption affecting drug absorption
• •Severe uncontrolled infection or comorbidity, or moderate/severe renal impairment
• •Active pulmonary disease (interstitial pneumonia, COPD, asthma, tuberculosis history)
• •Abnormal coagulation (INR \> 2.0, PT \> 16 s), bleeding tendency, or thrombolytic/anticoagulant therapy (except prophylaxis)
• •Significant bleeding within 3 months (e.g., hemoptysis ≥ 2.5 mL, GI bleeding, varices, ulcers, vasculitis)
• •Known hereditary/acquired bleeding or thrombotic disorders (e.g., hemophilia, thrombocytopenia)
• •History of substance abuse or mental disorders affecting compliance
• •Use of warfarin or coumarin derivatives within 14 days before or during treatment
• •Other severe acute/chronic conditions increasing risk or confounding results
• •Poor compliance or other conditions deemed unsuitable for trial participation